The emperor has no clothes: Dementia treatment on the eve of the aging era

Journal of the American Geriatrics Society

Volumn 53, Issue 1, 2005, Pages 163-164

  Royall, Donald R ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; MEMANTINE; PLACEBO; DOPAMINE RECEPTOR STIMULATING AGENT;

AGING; ALZHEIMER DISEASE; CEREBROVASCULAR DISEASE; CLINICAL RESEARCH; DEMENTIA; DIAGNOSTIC ERROR; DIFFUSE LEWY BODY DISEASE; DRUG APPROVAL; DRUG EFFICACY; EDITORIAL; EVIDENCE BASED MEDICINE; HUMAN; AGED; CLINICAL PRACTICE; CLINICAL TRIAL; PRACTICE GUIDELINE;

AGED; AGING; CHOLINESTERASE INHIBITORS; CLINICAL TRIALS; DEMENTIA; DOPAMINE AGENTS; EVIDENCE-BASED MEDICINE; HUMANS; MEMANTINE; PHYSICIAN'S PRACTICE PATTERNS; PLACEBOS; PRACTICE GUIDELINES;

EID: 14544297496     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2005.53029.x     Document Type: Editorial

References (25)

1. Grady D. Nominal benefits seen in drugs for Alzheimer's. New York Times April 7, 2004.
2. Doody RS, Stevens JC, Beck C et al. Practice parameter. Management of dementia: An evidence based review. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1154-1166.
3. Weinberg AD. Alzheimer's Disease. Considerations, Challenges, and Consequences [on-line]. Available at http://hybridpub.com/eldercare/Weinbergalz. html. Accessed April 12, 2004.
4. Karlawish JHT, Whitehouse PJ. Is the placebo control obsolete in a world after donepezil and vitamin E? Arch Neurol 1998;55:1420-1424.
5. Mohs RC, Rosen WG, Davis KL. The Alzheimer Disease Assessment Scale: An instrument for assessing treatment efficacy. Psychopharmacol Bull 1983;19: 448-450.
6. Geldmacher DS. Alzheimer's disease. Current pharmacotherapy in the context of patient and family needs. J Am Geriatr Soc 2003;51:S289-S295.
7. Doody RS, Geldmacher DS, Gordon B et al. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 2001;58:427-433.
8. Farlow M. Long-term cognitive benefits associated with the use of rivastigmine in the treatment of Alzheimer's disease [Abstract]. J Am Geriatr Soc 2000; 48:S108.
9. Feldman H, Gracon S. Alzheimer's disease: Symptomatic drugs under development. In: Gauthier S, ed. Clinical Diagnosis and Management of Alzheimer's Disease. London: Martin Dunitz, 1996, pp 239-259.
10. McKeith IG, Fairbairn AF, Perry RH et al. The clinical diagnosis and misdiagnosis of senile dementia of Lewy body type (SDLT). Br J Psychiatry 1994;165:324-332.
11. McKeith I, Del Ser T, Spano P et al. Efficacy of rivastigmine in dementia with Lewy bodies: A randomized, double-blind, placebo-controlled international study. Lancet 2000;356:2031-2036.
12. Brun A, Englund E. A white matter disorder in dementia of the Alzheimer type: A pathoanatomical study. Ann Neurol 1986;19:253-262.
13. Vermeer SE, Koudstaal PJ, Oudkerk M et al. Prevalence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. Stroke 2002;33:21-25.
14. Vermeer SE, Den Heijer T, Koudstaal PJ et al. Incidence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. Stroke 2003;34:392-396.
15. Goulding JM, Signorini DF, Chatterjee S et al. Inverse relation between Braak stage and cerebrovascular pathology in Alzheimer predominant dementia. J Neurol Neurosurg Psychiatr 1999;67:654-657.
16. Bowler JV, Munoz DG, Mersky H et al. Fallacies in the pathological confirmation of the diagnosis of Alzheimer's disease. J Neurol Neurosurg Psychiatr 1998;64:18-24.
17. Mayeux R, Saunders AM, Shea S et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. N Engl J Med 1998;338:506-511.
18. Mesulam M, Siddique T, Cohen B. Cholinergic denervation in a pure multiinfarct state. Observations on CADASIL. Neurology 2003;60:1183-1185.
19. Erkinjuntti T, Skoog I, Lane R et al. Potential long-term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brains. Int J Clin Pract 2003;57:756-760.
20. De Kosky ST. Pathology and pathways of Alzheimer's disease with an update on new developments in treatment. J Am Geriatr Soc 2003;51:S314-S320.
21. Lopez OL, Becker JT, Wisniewski S et al. Cholinesterase inhibitor treatment alters the natural history of Alzheiemer's disease. J Neurol Neurosurg Psychiatr 2002;72:310-314.
22. Geldmacher DS, Provenzano G, McRae T et al. Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. J Am Geriatr Soc 2003;51:937-944.
23. Royall DR. Donepezil's effects remain uncertain. J Am Geriatr Soc 1990;52:843-845.
24. VHA Pharmacy Benefits Management Strategic Healthcare Group Alzheimer's Disease Workgroup and the Medical Advisory Panel. Criteria for the use of memantine (Namenda) [on-line]. Available at www.vapbm.org/criteria/memantine. pdf. Accessed April 12, 2004.
25. Kukull WA, Larson EB, Reifler BV et al. The validity of 3 clinical diagnostic criteria for Alzheimer's disease. Neurology 1990;40:1364-1369.